Company intelligence / Profile preview

Aravax

Melbourne, Victoria, Australiaaravax.com.au ↗

Ownership: Private
Development stage: Phase 2

Overview

Aravax has completed recruitment for its Phase 2 study of PVX108 for peanut allergy treatment. The study is being conducted in Australia and the USA with results expected in H1 2026[6]. The company is approaching Phase 3 development for its lead candidate PVX108[5].

Therapeutic areas: Immunology
Modalities: Peptide-based immunotherapies
Industry: Biotech

Drug pipeline

2 assets

PVX108

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Aravax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aravax.

Explore the full profile